gentamicin

(redirected from Gentamycin)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to Gentamycin: vancomycin

gentamicin

 [jen″tah-mi´sin]
an aminoglycosideantibiotic complex elaborated by bacteria of the genus Micromonospora, effective against many gram-negative bacteria, especially Pseudomonas species, as well as certain gram-positive bacteria, especially Staphylococcus aureus; used as the sulfate salt.

gen·ta·mi·cin

(jen'tă-mī'sin), Avoid the misspelling gentamycin.
A broad spectrum antibiotic of the aminoglycoside class, obtained from Micromonospora purpurea and M. echinospora, which inhibits the growth of both gram-positive and gram-negative bacteria; the sulfate salt is used medicinally.

gentamicin

(jĕn′tə-mī′sĭn)
n.
A broad-spectrum antibiotic derived from an actinomycete of the genus Micromonospora, used in its sulfate form to treat various infections.

gentamicin

Garamycin® Infectious disease A broad-spectrum aminoglycoside antibiotic obtained from Micromonospora purpurea Adverse effects Ototoxicity, nephrotoxicity Therapeutic range Peak 5-10 mg/L; trough < 2 mg/L Toxic range Peak > 10 mg/L; trough > 2 mg/L. See Aminoglycosides.

gen·ta·mi·cin

(jen'tă-mī'sin) Avoid the misspelling gentamycin.
A broad spectrum antibiotic of the aminoglycoside class, which inhibits growth of both gram-positive and gram-negative bacteria; sulfate salt is also used medicinally.

gentamicin

An aminoglycoside antibiotic used mainly for the treatment of serious GRAM NEGATIVE infections. Otherwise, gentamicin is used topically for external infections, such as those of the eye or ear. In large dosage it can cause TINNITUS, deafness and kidney damage. Recently, gentamycin has been shown to be capable of bypassing a STOP MUTATION and has been shown to be helpful in controlling CYSTIC FIBROSIS and other genetic disorders caused by stop mutations. The drug is on the WHO official list. Brand names are Cidomycin, Garamycin, Genticin and Minims gentamicin. See also PTC124.

antibiotic 

1. Pertaining to the ability to destroy or inhibit other living organisms.
2. A substance derived from a mould or bacterium, or produced synthetically, that destroys (bactericidal) or inhibits the growth (bacteriostatic) of other microorganisms and is thus used to treat infections. Some substances have a narrow spectrum of activity whereas others act against a wide range of both gram-positive and gram-negative organisms (broad-spectrum antibiotics). Antibiotics can be classified into several groups according to their mode of action on or within bacteria: (1) Drugs inhibiting bacterial cell wall synthesis, such as bacitracin, vancomycin and the β-lactams based agents (e.g. penicillin, cephalosporins (e.g. ceftazidime, ceftriaxone, cefuroxime). (2) Drugs affecting the bacterial cytoplasmic membrane, such as polymyxin B sulfate and gramicidin. (3) Drugs inhibiting bacterial protein synthesis, such as aminoglycosides (e.g. amikacin sulfate, framycetin sulfate, gentamicin, neomycin sulfate and tobramycin), tetracyclines, macrolides (e.g. erythromycin and azithromycin) and chloramphenicol. (4) Drugs inhibiting the intermediate metabolism of bacteria, such as sulfonamides (e.g. sulfacetamide sodium) and trimethoprim. (5) Drugs inhibiting bacterial DNA synthesis, such as nalixidic acid and fluoroquinolones (e.g. ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin). (6) Other antibiotics such as fusidic acid, the diamidines, such as propamidine isethionate and dibrompropamidine. Syn. antibacterial. See antiinflammatory drug; fusidic acid.

gen·ta·mi·cin

(jen'tă-mī'sin)
Broad spectrum aminoglycoside antibiotic that inhibits growth of both gram-positive and gram-negative bacteria.
References in periodicals archive ?
Antibiotic Susceptibility in Bile Culture Positive Subjects Antibiotics Susceptible Resistant Penicillin 57% 43% Ampicilin 43% 57% Cefotaxim 62% 38% Ceftriaxone 71% 29% Cefepime 71% 29% Imipenem 67% 33% Amikacin 76% 24% Gentamycin 67% 33% Erythromycin 52% 48% Clindamycin 38% 62% Ciprofloxacin 67% 33% Sulfamethoxazole-tm 48% 52% Tetracycline 43% 57% Table 3.
Upon analyzing the antibiotic sensitivity results it was evident that the antibiotics with the highest bacterial susceptibility in this study were gentamycin followed by ciprofloxacin and cefotaxime: this is in line with a study conducted by Garba BI et al who found highest bacterial susceptibility rate in this study were ciprofloxacin, ofloxacin and gentamicin.
Dublin Antimicrobial disc Marbofloxacin 10[micro]g S S R Enrofloxacin 10[micro]g S S S Gentamycin 10[micro]g R R R Erythromycin 15[micro]g R R R Cefotaxime 30[micro]g R R S Amoxicillin 10[micro]g R R R Penicillin 10 units S S S Tetracycline 30[micro]g R R S Streptomycin 10[micro]g R R S Trimeth/sulfa S S R 1.25/23.75[micro]g Spectinomycin 20[micro]g S S S Neomycin 20[micro]g S S S R: Resistant.
coli isolates had high to moderate resistance to ampicillin (56.65%), tetracycline (54.33%), kanamycin (52.75%), gentamycin (49.60%), vibramycin (46.45%), ceftriaxone (44.88%), norfloxacin (30.70%) and ciprofloxacin (25.98%).
In the present study the susceptibility pattern of Acinetobacter species recovered from different clinical specimen against various types of antibiotics was maximum with Cefepime 70%, Meropenem 66%, Pipercillin / Tazobactam 66%, Amikacin 66% followed by Ampicillin - Salbactum 59%, Gentamycin 50%, Ciprofloxacin 50%, Ceftriaxone 44%, Ceftazidime 40%, Tetracycline 31% and Trimethoprime sulfamethoxazole 22%.
Staphylococci were highly resistant to cloxacillin (28.6%) and oxacillin (21.0%) in the HIGH group, and streptococci were highly resistant to oxytetracycline (36.8% and 22.7%), gentamycin (73.7% and 77.3%) and neomycin (94.7% and 90.9%) in the NORM and HIGH group, respectively.
The patients used ceftriaxone, augmentin, and ampicillin plus cloxacillin (ampiclox) with gentamycin ointment respectively(table 3), to control the infections before presentation for treatment.
The less effective antimicrobial susceptibility pattern was seen with cefepime (67.4%), ciprofloxacin (56.5%), amikacin (52.0%), aztreonam and gentamycin (50.0% each) and co-trimoxazole (43.5%).
The absence of resistance to gentamycin observed, even though in contrast with the 25% resistance reported by Saenz et al.
* Treated empirically with IP vancomycin and gentamycin.